Prosecution Insights
Last updated: October 02, 2026
Application No. 18/008,771

DOCK TAG SYSTEM

Non-Final OA §103§112
Filed
Dec 07, 2022
Priority
Jun 12, 2020 — provisional 63/038,237 +1 more
Examiner
COFFA, SERGIO
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Glaxosmithkline Biologicals S.A.
OA Round
3 (Non-Final)
61%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
457 granted / 748 resolved
+1.1% vs TC avg
Strong +32% interview lift
Without
With
+32.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
69 currently pending
Career history
799
Total Applications
across all art units

Statute-Specific Performance

§101
3.6%
-36.4% vs TC avg
§103
34.4%
-5.6% vs TC avg
§102
16.8%
-23.2% vs TC avg
§112
26.7%
-13.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 748 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6/24/2026 has been entered. Claim Status Claims 1-4, 7-8, 12-15, 25, 69 and 74-76 are pending. Claims 78-79 have been canceled. Claims 1, 4, 12-15 and 69 have been amended. Claims 4, 7-8 and 69 are allowable. Claims 1-3, 12-15, 25 and 74-76, previously withdrawn from consideration as a result of a restriction requirement, require all the limitations of an allowable claim. Pursuant to the procedures set forth in MPEP § 821.04(a), the restriction requirement between inventions I-X, as set forth in the Office action mailed on 10/16/2025, is hereby withdrawn and claims 1-3, 12-15, 25 and 74-76 are hereby rejoined and fully examined for patentability under 37 CFR 1.104. In view of the withdrawal of the restriction requirement, applicant(s) are advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Claim Objections Claim 25 is objected to because of the following informalities: Claim 25 should be amended to recite “….is selected from a sequence comprising SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, or SEQ ID NO: 33”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. This is a new rejection. Claim 8 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 8 recites the limitation "the heterologous antigenic polypeptide" in lines 1-2. There is insufficient antecedent basis for this limitation in the claim. Claim Rejections - 35 USC § 103 The rejection of claims 4, 7-8 and 69 under 35 U.S.C. 103 as being unpatentable over Berti et al. in view of Zhu et al. is withdrawn in view of the amendments to the claims. Double Patenting The rejection of claims 4, 7-8 and 69 on the ground of nonstatutory double patenting as being unpatentable over claims 1-18 of U.S. Patent No. 10245310 in view of Zhu et al. is withdrawn in view of the amendments to the claims. Allowable Subject Matter Claims 1-4, 7, 12-15, 69 and 74-76 are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SERGIO COFFA whose telephone number is (571)270-3022. The examiner can normally be reached M-F: 6AM-4PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MELISSA FISHER can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SERGIO COFFA Ph.D./ Primary Examiner Art Unit 1658 /SERGIO COFFA/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Dec 07, 2022
Application Filed
Dec 03, 2025
Non-Final Rejection mailed — §103, §112
Mar 03, 2026
Response Filed
Mar 25, 2026
Final Rejection mailed — §103, §112
Jun 24, 2026
Request for Continued Examination
Jun 25, 2026
Response after Non-Final Action
Aug 12, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735464
C-terminal CDNF and MANF fragments, pharmaceutical compositions comprising same and uses thereof
6y 10m to grant Granted Sep 15, 2026
Patent 12735463
PEPTIDE TAGS FOR LIGAND INDUCED DEGRADATION OF FUSION PROTEINS
5y 3m to grant Granted Sep 15, 2026
Patent 12735454
PEPTIDE COMPOUND TARGETING ELASTIN-DERIVED PEPTIDES AND USE THEREOF
3y 9m to grant Granted Sep 15, 2026
Patent 12735452
ADHESIVE PEPTIDES
3y 3m to grant Granted Sep 15, 2026
Patent 12698312
JNK3 INHIBITORY PEPTIDES
3y 8m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
61%
Grant Probability
94%
With Interview (+32.5%)
2y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 748 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month